These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23298904)

  • 1. Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma.
    Day KE; Beck LN; Heath CH; Huang CC; Zinn KR; Rosenthal EL
    Cancer Biol Ther; 2013 Mar; 14(3):271-7. PubMed ID: 23298904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.
    Day KE; Beck LN; Deep NL; Kovar J; Zinn KR; Rosenthal EL
    Laryngoscope; 2013 Nov; 123(11):2681-9. PubMed ID: 23616260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice.
    Heath CH; Deep NL; Beck LN; Day KE; Sweeny L; Zinn KR; Huang CC; Rosenthal EL
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):982-90. PubMed ID: 23525846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.
    Heath CH; Deep NL; Sweeny L; Zinn KR; Rosenthal EL
    Ann Surg Oncol; 2012 Nov; 19(12):3879-87. PubMed ID: 22669455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
    Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
    Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.
    Sweeny L; Prince A; Patel N; Moore LS; Rosenthal EL; Hughley BB; Warram JM
    Laryngoscope; 2016 Dec; 126(12):E387-E395. PubMed ID: 27576611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer.
    Korb ML; Hartman YE; Kovar J; Zinn KR; Bland KI; Rosenthal EL
    J Surg Res; 2014 May; 188(1):119-28. PubMed ID: 24360117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Dosing Strategy for Fluorescence-Guided Surgery with Panitumumab-IRDye800CW in Head and Neck Cancer.
    Nishio N; van den Berg NS; van Keulen S; Martin BA; Fakurnejad S; Zhou Q; Lu G; Chirita SU; Kaplan MJ; Divi V; Colevas AD; Rosenthal EL
    Mol Imaging Biol; 2020 Feb; 22(1):156-164. PubMed ID: 31054001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.
    Rosenthal EL; Kulbersh BD; King T; Chaudhuri TR; Zinn KR
    Mol Cancer Ther; 2007 Apr; 6(4):1230-8. PubMed ID: 17431103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW.
    Warram JM; de Boer E; Korb M; Hartman Y; Kovar J; Markert JM; Gillespie GY; Rosenthal EL
    Br J Neurosurg; 2015; 29(6):850-8. PubMed ID: 26073144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Early Therapeutic Effects after Near-Infrared Photoimmunotherapy (NIR-PIT) Using Luciferase-Luciferin Photon-Counting and Fluorescence Imaging.
    Maruoka Y; Nagaya T; Nakamura Y; Sato K; Ogata F; Okuyama S; Choyke PL; Kobayashi H
    Mol Pharm; 2017 Dec; 14(12):4628-4635. PubMed ID: 29135265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study.
    Houvast RD; Baart VM; Bhairosingh SS; Cordfunke RA; Chua JX; Vankemmelbeke M; Parsons T; Kuppen PJK; Durrant LG; Vahrmeijer AL; Sier CFM
    Mol Imaging Biol; 2020 Dec; 22(6):1511-1522. PubMed ID: 32780212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-labeled anti-GD2 targeted probe for intraoperative molecular imaging of neuroblastoma.
    Rosenblum LT; Sever RE; Gilbert R; Guerrero D; Vincze SR; Menendez DM; Birikorang PA; Rodgers MR; Jaswal AP; Vanover AC; Latoche JD; Cortez AG; Day KE; Foley LM; Sneiderman CT; Raphael I; Hitchens TK; Nedrow JR; Kohanbash G; Edwards WB; Malek MM
    J Transl Med; 2024 Oct; 22(1):940. PubMed ID: 39407274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid, non-invasive fluorescence margin assessment: Optical specimen mapping in oral squamous cell carcinoma.
    van Keulen S; van den Berg NS; Nishio N; Birkeland A; Zhou Q; Lu G; Wang HW; Middendorf L; Forouzanfar T; Martin BA; Colevas AD; Rosenthal EL
    Oral Oncol; 2019 Jan; 88():58-65. PubMed ID: 30616798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.
    Miller SE; Tummers WS; Teraphongphom N; van den Berg NS; Hasan A; Ertsey RD; Nagpal S; Recht LD; Plowey ED; Vogel H; Harsh GR; Grant GA; Li GH; Rosenthal EL
    J Neurooncol; 2018 Aug; 139(1):135-143. PubMed ID: 29623552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors.
    Baart VM; van Manen L; Bhairosingh SS; Vuijk FA; Iamele L; de Jonge H; Scotti C; Resnati M; Cordfunke RA; Kuppen PJK; Mazar AP; Burggraaf J; Vahrmeijer AL; Sier CFM
    Mol Imaging Biol; 2023 Feb; 25(1):122-132. PubMed ID: 34642899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Patient-Derived Orthotopic Gastric Cancers with a Fluorescent Humanized Anti-CEA Antibody.
    Cox KE; Turner MA; Lwin TM; Amirfakhri S; Kelly KJ; Hosseini M; Ghosh P; Obonyo M; Hoffman RM; Yazaki PJ; Bouvet M
    Ann Surg Oncol; 2024 Sep; 31(9):6291-6299. PubMed ID: 38888861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study.
    Morlandt AB; Moore LS; Johnson AO; Smith CM; Stevens TM; Warram JM; MacDougall M; Rosenthal EL; Amm HM
    J Oral Maxillofac Surg; 2020 Oct; 78(10):1736-1747. PubMed ID: 32554066
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.